Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.8%

14 terminated/withdrawn out of 778 trials

Success Rate

92.5%

+6.0% vs industry average

Late-Stage Pipeline

10%

79 trials in Phase 3/4

Results Transparency

3%

5 of 173 completed trials have results

Key Signals

180 recruiting5 with results6 terminated8 withdrawn

Enrollment Performance

Analytics

N/A
234(45.2%)
Phase 2
122(23.6%)
Phase 1
78(15.1%)
Phase 3
48(9.3%)
Phase 4
31(6.0%)
Early Phase 1
5(1.0%)
518Total
N/A(234)
Phase 2(122)
Phase 1(78)
Phase 3(48)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (778)

Showing 20 of 778 trials
NCT07534371Active Not Recruiting

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

Role: lead

NCT07533825Not ApplicableEnrolling By Invitation

Laparoscopic Staging for Stage III Gastric Cancer

Role: collaborator

NCT07518966Recruiting

Association Between Early Recurrence and Long-Term Recurrence After Pulsed Field Ablation for Atrial Fibrillation: Prospective Real-World Evidence From China

Role: lead

NCT07081074Not ApplicableRecruiting

ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer

Role: lead

NCT07086638Not ApplicableRecruiting

ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer

Role: lead

NCT06865521Not ApplicableActive Not Recruiting

Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer

Role: lead

NCT07040943Phase 1Recruiting

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Role: lead

NCT07510308Phase 1Recruiting

Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients

Role: lead

NCT07518979Phase 2Not Yet Recruiting

EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer

Role: collaborator

NCT07508046Completed

Clinical Study on the Expression of PHGDH and Its Prognostic Value in Colorectal Cancer Patients Receiving Immunotherapy

Role: lead

NCT06654297Phase 1Active Not Recruiting

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Role: lead

NCT07507097Not ApplicableNot Yet Recruiting

Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke

Role: lead

NCT07467083Phase 3Recruiting

Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy

Role: lead

NCT07492914Phase 2Not Yet Recruiting

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Role: lead

NCT07339774Phase 2Recruiting

Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.

Role: lead

NCT07282483Phase 2Recruiting

Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients

Role: lead

NCT07457281Phase 1Recruiting

GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study

Role: lead

NCT05847855Recruiting

Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors

Role: collaborator

NCT07353671Phase 2Recruiting

Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis

Role: lead

NCT07490990Not Yet Recruiting

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Role: lead